Cited by 250Treatment of Major DepressionElectroconvulsive Therapy StudiesTranscranial Magnetic Stimulation Studies

Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects

Open access
Nugent, Allison C., Ballard, Elizabeth D., Gould, Todd D., Park, Lawrence T., Moaddel, Ruin, Brutsche, Nancy E., Zarate, Carlos A.·2019·Molecular Psychiatry

Abstract

Ketamine's mechanism of action was assessed using gamma power from magnetoencephalography (MEG) as a proxy measure for homeostatic balance in 35 unmedicated subjects with major depressive disorder (MDD) and 25 healthy controls enrolled in a double-blind, placebo-controlled, randomized cross-over trial of 0.5 mg/kg ketamine. MDD subjects showed significant improvements in depressive symptoms, and healthy control subjects exhibited modest but significant increases in depressive symptoms for up to 1 day after ketamine administration. Both groups showed increased resting gamma power following ketamine. In MDD subjects, gamma power was not associated with the magnitude of the antidepressant effect. However, baseline gamma power was found to moderate the relationship between post-ketamine gamma power and antidepressant response; specifically, higher post-ketamine gamma power was associated with better response in MDD subjects with lower baseline gamma, with an inverted relationship in MDD subjects with higher baseline gamma. This relationship was observed in multiple regions involved in networks hypothesized to be involved in the pathophysiology of MDD. This finding suggests biological subtypes based on the direction of homeostatic dysregulation and has important implications for inferring ketamine's mechanism of action from studies of healthy controls alone.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41380-018-0028-2

Cites

90 of 90 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Animal studies show that ketamine-induced increases in synaptic proteins and density.

    “While animal studies show that ketamine-induced increases in synaptic proteins and density 14 67 40”

    From Imaging the effect of ketamine on synaptic density (SV2A) in the living brain (2022) · cites this paper as [67]

    The Introduction (page unavailable) reports that preclinical studies found ketamine rapidly induces synaptogenesis and reverses stress-related synaptic deficits, supporting the claim’s general point about increased synapses. It does not state that animal studies found increases in synaptic proteins or explicitly report a measure of synaptic density. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • Gamma power has been found to be consistently increased after subanesthetic ketamine administration in participants with depression.

    “Gamma power has been found to be consistently increased after subanesthetic ketamine administration in participants with depression [205,206]”

    From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [205]

  • PET is generally not as sensitive as techniques such as Western blot analysis and two-photon microscopy.

    “PET is generally not as sensitive as techniques such as Western blot analysis and two-photon microscopy 67”

    From Imaging the effect of ketamine on synaptic density (SV2A) in the living brain (2022) · cites this paper as [67]

    The Materials and Methods passages describe MEG analysis, and the Discussion addresses gamma power; neither compares PET with Western blot analysis or two-photon microscopy. Searches for those techniques and for PET sensitivity found no passage addressing the claimed comparison. Page numbers are unavailable in our copy. (LLM, conf=0.75)

    Experimental — accuracy not yet measured
  • Lower baseline gamma power and subsequent elevation after ketamine administration have been shown to predict better antidepressant responses in TRD.

    “In that regard, lower baseline gamma power (reflective of GABA and glutamate functional balance) and subsequent elevation after ketamine administration have been shown to predict better antidepressant responses in TRD [88], though further validation is needed.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. [40]First MB Spitzer RL Gibbon M Williams AR Structured Clinical Interview for DSM-IV TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P) New York New York State Psychiatric Institute, Biometrics Research 2001
  2. [60]Robinson SE Vrba J Functional neuroimaging by synthetic aperture magnetometry (SAM) Biomag Tohoku University Press Sendai 1999 302 305

Cited by

Sorted by citations

Authors
Nugent, A. C., Ballard, E. D., Gould, T. D., Park, L. T., Moaddel, R., Brutsche, N. E., & Zarate, C. A.
Affiliations
  • National Institutes of Health (US)
  • University of Maryland, Baltimore (US)
  • National Institute on Aging (US)
Corresponding author
Nugent, Allison C.
Venue
Molecular Psychiatry
Published
2018-02-27
Volume
24
Issue
7
Pages
1040-1052
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
OpenAlex
W2792218734
Cited by
250
References
90
Citations by year
2026: 16 · 2025: 30 · 2024: 20 · 2023: 30 · 2022: 21 · 2021: 60 · 2020: 33 · 2019: 23 · 2018: 17
FWCI
21.46
Type
journal article
Language
en
Open access
Locations
  • Molecular Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • U.S. Department of Veterans Affairs (I01BX004062)
  • National Alliance for Research on Schizophrenia and Depression
  • National Institutes of Health (Z99 MH999999)
  • National Institute of Mental Health (Z01MH002857, R01MH107615, ZIAMH002857)
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
Keywords
ketamine, major depressive disorder, gamma power, resting-state brain activity, homeostatic balance, antidepressant response, magnetoencephalography
MeSH terms
Adult, Antidepressive Agents, Depression, Major Depressive Disorder, Double-Blind Method, Female, Humans, Ketamine, Male, Middle Aged, Magnetoencephalography, Case-Control Studies, Cross-Over Studies, Electrophysiological Phenomena, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review